BONESUPPORT HOLDING AB (publ) – Publishes Q2 2023 interim report

Published: 2023-07-13

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2023.

STRONG MOMENTUM FOR CERAMENT G IN THE US

APRIL – JUNE 2023

  • Net sales increased by 88 percent (75 percent at constant exchange rates) and amounted to SEK 140.4 million (74.6).
  • The North America (NA) segment reported a sales growth of 126 percent (107 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (24 percent at constant exchange rates).
  • The gross margin amounted to 91.3 percent (89.0).
  • Operating result before effects from the Group’s incentive programs amounted to SEK +13.6 million (-9.1). Reported operating result amounted to SEK +6.0 million (-14.9).
  • Earnings per share before dilution were SEK +0.08 (-0.25).
  • Earnings per share after dilution were SEK +0.08 (-0.25).

JANUARY – JUNE 2023

  • Net sales increased by 85 percent (72 percent at constant exchange rates) and amounted to SEK 260.1 million (141.0).
  • The North America (NA) segment reported a sales growth of 118 percent (100 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (27 percent at constant exchange rates).
  • The gross margin amounted to 90.9 percent (89.7)
  • Operating result before effects from the Group’s incentive programs amounted to SEK +18.2 million (-21.6). Reported operating result amounted to SEK +6.7 million (-31.3).
  • Earnings per share before dilution were SEK +0.09 (-0.51).
  • Earnings per share after dilution were SEK +0.08 (-0.51).

"Strong quarter, with increased market penetration for CERAMENT G." Emil Billbäck, CEO


EVENTS DURING THE REPORTING PERIOD

  • In May, a study was published of 53 patients, with an average follow-up time of 30 months, in which 100 percent of patients were able to avoid amputation when using CERAMENT G/V in the treatment of complex diabetic foot osteomyelitis cases.
  • Strong long-term data with CERAMENT G for severe open fractures were presented in a study from Manchester University Hospital in May. The study was conducted with 81 patients with a mean follow-up time of 55.8 months.

EVENTS AFTER THE REPORTING PERIOD
Nothing to report.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-13 08:00 CEST.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 329 million in 2022. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

BONESUPPORT Q2 2023 EN